562P - Peritumoral lymphoid infiltrate in renal cell carcinoma

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Renal Cell Cancer
Pathology/Molecular Biology
Presenter Olga Oleshko
Citation Annals of Oncology (2016) 27 (suppl_9): ix181-ix183. 10.1093/annonc/mdw602
Authors O. Oleshko1, I. Bobrov2, T. Cherdantseva1, A. Lazarev3
  • 1Department Of Histology, Embryology, Cytology, Altai state medical university, 656038 - Barnaul/RU
  • 2Department Of Pathological Anatomy, Altai state medical university, 656038 - Barnaul/RU
  • 3Department Of Oncology, Altai Branch of N. N. Blokhin Russian Cancer Research Centre, 656049 - Barnaul/RU

Abstract

Background

Recent studies point out the important role of the immune system in the progression of renal cell carcinoma (RCC). Numerous articles show the value of intratumoral lymphocytic infiltration. However, there are few studies on the importance of peritumoral lymphocytic infiltrate, and the results are contradictory. Therefore, the study of the local immune response, which is represented by peritumoral lymphoid infiltrate, is very significant. The aim of the study was to evaluate the relationship between clinicopathologic parameters and density of lymphoid infiltrate (DLI) in the peritumoral zone (PZ). In addition, the objective was to figure out whether DLI in PZ is a prognostic factor for survival of RCC patients.

Methods

Postoperative material from 129 patients with RCC has been studied. The average age of the patients was 57,8 ± 9,7 years. DLI in PZ was evaluated at a 1000x magnification in 5 fields of view using tissue specimens stained with hematoxylin and eosin. Statistical analysis was carried out using the program Statistica 6.1.

Results

We revealed a correlation between DLI and: 1) TNM stage (r = 0,312; p 

Conclusions

Based on our findings, we believe that high DLI in PZ found at RCC patients can be attributed to a negative prognostic marker.

Clinical trial indentification

All patients signed the informed consent form approved by the Research Ethics Committee (REC 15/2015)

Legal entity responsible for the study

Altai Branch of N. N. Blokhin Russian Cancer Research Centre, Barnaul, Russia

Funding

Altai Branch of N. N. Blokhin Russian Cancer Research Centre, Barnaul, Russia

Disclosure

All authors have declared no conflicts of interest.